Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
International Association for the Treatment of Sexual Offenders (every single person's treatment and care is going to be different to what best fits that specific person). Every sex offender is different which is why their care and limits need to be properly customized for that individual in order to protect the people of the community and also to successfully prevent them from reoffending. The management of risk is an important part of treatment, but if there is only a limited focus on risk then it can lead to excessively confrontational therapeutic encounters, no close relationship between the offenders and clinicians (this can potentially make treatment unsuccessful because there